LMNL - Liminal BioSciences repays $39.1M debt to Structured Alpha
Liminal BioSciences (NASDAQ:LMNL) repaid its debt of $39.1M to Structured Alpha in full, using cash on hand. The loan repayment terminates LMNL's creditor relationship with Structured Alpha. Early repayment resulted in total interest savings of C$9.1M. The repayment was funded with cash generated from the sale of a pediatric review voucher and the divestment of LMNL's plasma-derived therapeutics business in 2021. No premiums or penalties were required in connection with the repayment. "The debt was due for repayment no later than Apr. 2024 and represented a significant overhang on our balance sheet, which we are pleased to have eliminated," said LMNL CEO Bruce Pritchard.
For further details see:
Liminal BioSciences repays $39.1M debt to Structured Alpha